DOAC-Stop™ removes all types of Direct Oral Anti-Coagulants (DOACs; dabigatran, apixaban, rivaroxaban, and edoxaban, etc) from test plasmas with minimal effect on underlying blood clotting tests. Just add one mini-tablet per 1ml test plasma (volume is not critical), mix for 5 minutes and centrifuge down the adsorbent. The resulting plasma is then depleted of DOACs and yields similar APTT, dRVVT , PT(INR) and other results as if DOACs had not been present.

Reversing agents coming into therapeutic use for individual DOACs are not widely available for lab tests. DOAC-Stop™ is now offered for simplifying the diagnostic problems associated with DOACs. It absorbs up to an estimated 2,000ng/ml of any DOAC in less than 5 minutes. Unlike therapeutic additives for reversing DOACs it leaves no residual effect. It can be used for checking if DOACs are present in samples giving unexpectedly prolonged clotting test or abnormal chromogenic test results. There is negligible interference with vitamin K antagonist or heparinoid anticoagulants. Plasmas treated with DOAC-Stop™ can be used for valid factor assays and in testing for thrombotic risk. In particular it can prevent false LAC positive results due to DOACs or other agents in testing for lupus anticoagulants. Currently RUO. Patent pending.

Please contact Haematex Research ( for more information.


DOAC-Stop™ is a CE marked product made to the exact specifications of Haematex Research Pty Ltd. Other products imitating DOAC-Stop™ and claiming to perform similarly may not do so. Test result findings reported for DOAC-Stop™ in publications may not be repeatable with copycat products.

For quick supply of genuine DOAC-Stop™ products contact our distributors or Haematex directly.



Recent papers on DOAC-Stop™ published in peer-reviewed journals:

1. Exner T, et al."Simple method for removing DOACs from plasma samples" Thromb. Res. 2018; 163: 117-122.

2. Favresse J, et al."Evaluation of the DOAC Stop procedure to overcome the effect of DOACs on several thrombophilia screening tests". TH Open, 2018; 2: e202-e209.

3. Jacquemin M, et al."The adsorption of dabigatran is as efficient as addition of idarucizumab to neutralize the drug in routine coagulation assays". Int. J. Lab. Haematol. 2018; 40: 442-447.

4. Kopatz WF, et al."Use of DOAC Stop for elimination of anticoagulants in thrombin generation assays". Thromb. Res. 2018; 170: 97-101.

5. Exner T, et al."Effect of an activated charcoal product (DOAC Stop™) intended for extracting DOACs on various other APTT-prolonging agents". Clin Chem Lab Med. 2019; 57: 690-696.

6. Platton S, Hunt C."Influence of DOAC Stop on coagulation assays in samples from patients on rivaroxaban or apixaban". Int J Lab Haematol. 2018; 1-7.

7. Exner T, et al."Clotting test results correlate better with DOAC concentrations when expressed as a "Correction Ratio"; results before/after extraction with the DOAC Stop reagent". Thromb Res 2019; 179: 69-72

8. Zabczyk M, et al."The effect of DOAC-Stop on lupus anticoagulant testing in plasma samples of venouse thromboembolism patients receiving direct oral anticoagulants". De Gruyter Clin Chem Lab Med 2019;



Haemochrom Diagnostica GmbH
Renteilichtung 1
DE-45134 Essen
Phone: +49 (0)201 8 43 77-0
Fax: +49 (0)201 53 64 56

Keurenplein 5
1069 CD Amsterdam
Phone: +31 (0)20 610 80 06
Fax: +31 (0)20 610 27 91
Ordering: ordering@nodia.n

Quadratech Diagnostics Ltd
P.O. Box 167
Surrey, KT18 7YL
Phone: +44(0)33 3321 2371
Fax: +44(0)33 3321 2372

Diapharma Group, Inc.
8948 Beckett Road
West Chester, OH 45069
Customer Service and Orders: 1.800.526.5224
Technical Support and Product Information: 1.800.447.3846
Local: 513.860.9324
Fax: 513.860.9635

Diagnostica, a. s.
Za tratí 686
196 00 Praha 9-Čakovice
Phone: +420 266 315 909
Fax: +420 266 316 000